报告英格兰在抗菌药物耐药性英国行动计划目标方面的进展:英格兰抗菌药物使用与耐药性监测项目(ESPAUR)
本文概述了英格兰抗菌药物使用与耐药性监测项目(ESPAUR)自2013年以来的年度报告进展,重点介绍2022年11月最新报告的关键亮点,并提出了未来十年的关注领域建议。监测范围已从抗生素消耗和耐药性扩展到抗真菌药、抗病毒药(包括针对SARS-CoV-2的新型药物)和抗疟药,同时评估了专业和公众参与等关键管理干预措施以及NHSE改进措施的进展。
要点
- ESPAUR年度报告监测范围已从抗生素扩展至抗真菌药、抗病毒药和抗疟药。
- 报告评估了专业与公众参与等关键抗菌药物管理干预措施的效果。
- 作者提出了进入下一个十年时应重点关注的领域建议。
核心结论
- 英格兰通过ESPAUR年度报告持续监测抗菌药物使用与耐药性,并评估英国国家行动计划目标的进展。
研究设计与样本
- 本文为对ESPAUR年度监测报告的简要更新,重点介绍2022年11月发布的最新报告关键亮点。
主要发现
- 监测范围从最初的抗生素消耗和耐药性扩展到抗真菌药、抗病毒药(包括针对SARS-CoV-2的新型药物)和抗疟药。
- 报告评估了包括专业和公众参与倡议在内的关键管理干预措施,以及NHSE改进措施的进展。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The plans for a new antimicrobial utilization and resistance national surveillance programme, alongside the development of quality measures and methods to monitor unintended outcomes of antimicrobial stewardship and both public and professional behaviour interventions were published in 2013. Since then, England has published an annual surveillance report including outlining progress against the ambitions of the UK national action plans on antimicrobial resistance (2013 to 2018 and 2019 to 2024). A decade later we provide a brief update on progress so far, with a focus on key highlights from the latest report published in November 2022. We also provide our recommendations for areas of focus as we move into the next decade. From an initial focus on antibiotic consumption and resistance, the report now includes surveillance data for antifungals, antivirals (including novel agents, such as those targeting SARS-CoV-2) and antimalarials. Evaluation of key stewardship interventions including professional and public engagement initiatives are also reported, as well as progress against NHS England's (NHSE's) improvement measures.
引用
- Ashiru-Oredope D, Cunningham N, Casale E, et al. Reporting England's progress towards the ambitions in the UK action plan for antimicrobial resistance: the English surveillance programme for antimicrobial utilisation and resistance (ESPAUR). J Antimicrob Chemother. 2023. PMID: 37596897. doi:10.1093/jac/dkad248
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。